Table Filtering
Other Information
Release Statistics Download
GlyCosmos Glycolipids

Glycolipid entries from the LIPID MAPS Structure Database (LMSD).

Source Last Updated
LIPID MAPS Proteome Database (LMSD) June 16, 2024
Displaying entries 2551 - 2575 of 3913 in total
Main Class Sub Class LM ID Name LipidBank ID KEGG ID PubChem CID ChEBI ID Exact Mass ▼ Formula
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AC08
  • Forssman antigen(d18:1/26:1(17Z))
  • GalNAcalpha1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44260187 1567.970167 C78H141N3O28
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AD08
  • GalNAcbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
  • Para-Forssman x3b(d18:1/26:1(17Z))
44260195 1567.970167 C78H141N3O28
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BC08
  • GalNAcbeta1-3(GalNAcbeta1-4)Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44260395 1567.970167 C78H141N3O28
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BD08
  • GlcNAcbeta1-6GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44260403 1567.970167 C78H141N3O28
Neutral glycosphingolipids GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) LMSP0503AC08
  • GalNAcbeta1-3Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44260507 1567.970167 C78H141N3O28
Neutral glycosphingolipids GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) LMSP0503AE08
  • GlcNAcbeta1-3Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44260523 1567.970167 C78H141N3O28
Neutral glycosphingolipids GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) LMSP0503AO08
  • GalNAcbeta1-4(Galbeta1-4GlcNAcbeta1-3)Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44260603 1567.970167 C78H141N3O28
Neutral glycosphingolipids Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AJ08
  • GlcNAcbeta1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44260691 1567.970167 C78H141N3O28
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AK08
  • GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
  • nLc5Cer(d18:1/26:1(17Z))
44261059 1567.970167 C78H141N3O28
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505BN08
  • GalNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
  • P antigen(d18:1/26:1(17Z))
44261291 1567.970167 C78H141N3O28
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CE08
  • GlcNAcalpha1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44261427 1567.970167 C78H141N3O28
Neutral glycosphingolipids Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AD08
  • Forssman-like iGb4(d18:1/26:1(17Z))
  • GalNAcalpha1-3GalNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44261867 1567.970167 C78H141N3O28
Neutral glycosphingolipids Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AO08
  • GalNAcbeta1-3Galalpha1-3(GlcNAcbeta1-6)Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44261931 1567.970167 C78H141N3O28
Neutral glycosphingolipids Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BG08
  • GlcNAcbeta1-3Galalpha1-3(GalNAcbeta1-4)Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44261683 1567.970167 C78H141N3O28
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AN03
  • Galalpha1-3Galalpha1-3Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44260270 1565.891644 C74H135NO33
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AI02
  • Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
  • type IV H(d18:1/18:0)
44260229 1562.891978 C74H134N2O32
Neutral glycosphingolipids Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502BM02
  • Fucalpha2-3Galbeta1-3GalNAcbeta1-4Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44260469 1562.891978 C74H134N2O32
Neutral glycosphingolipids GalNAcbeta1-4Galbeta1-4Glc- (Ganglio series) LMSP0503AK02
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44260565 1562.891978 C74H134N2O32
Neutral glycosphingolipids Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AE02
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
  • type I B antigen(d18:1/18:0)
44260645 1562.891978 C74H134N2O32
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AE02
  • Galalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
  • type II B antigen(d18:1/18:0)
44261005 1562.891978 C74H134N2O32
Neutral glycosphingolipids Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CV02
  • Gala 1-3Lex(d18:1/18:0)
  • Galalpha1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44261549 1562.891978 C74H134N2O32
Neutral glycosphingolipids Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506AW02
  • Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44261613 1562.891978 C74H134N2O32
Neutral glycosphingolipids Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BB02
  • Fucalpha1-2Galbeta1-3GalNAcbeta1-3Galalpha1-3Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44261637 1562.891978 C74H134N2O32
Acidic glycosphingolipids Gangliosides LMSP0601BY02
  • NeuGcalpha2-3Galbeta1-3GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44262365 1561.871577 C73H131N3O32
Acidic glycosphingolipids Gangliosides LMSP0601CJ02
  • Galbeta1-3GalNAcbeta1-4(NeuGcalpha2-3)Galbeta1-4Glcbeta-Cer(d18:1/18:0)
44262437 1561.871577 C73H131N3O32

About Release Notes Help Feedback

Click here to visit the beta site.


International Collaboration

GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.

Acknowledgements

Supported by JST NBDC Grant Number JPMJND2204

Partly supported by NIH Common Fund Grant #1U01GM125267-01


Logo License Policies Site Map

Contact: support@glycosmos.org

This work is licensed under Creative Commons Attribution 4.0 International


GlyCosmos Portal v4.0.0

Last updated: August 19, 2024